Cort

Recent Posts

Valuing Pharmaceutical Assets: When to Use NPV vs rNPV

15th October 2019
Preview: A variety of approaches have been developed to evaluate pharmaceutical assets, but two similar yet distinct methods are most commonly used. Venture capitalists and large investment firms...
Learn More

Pharmaceutical Patent Term Extension: An Overview

27th March 2019
Pharmaceutical Patent Term Extension: An Overview About the authors: Scott Whittaker is an Alacrita Associate and Robert Johnson is Managing Partner of the firm’s Boston office. Anthony Walker is a...
Learn More

Pharmaceutical Probability of Success

19th October 2018
Abstract: Critical strategic decisions are made based on valuation models of pharmaceutical assets. Of the many assumptions that underpin a valuation model, probability of success is a key input, but...
Learn More
1

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-25 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.